Metraipolis › archive › dc_7f15fb8d7969

Efficacy and safety of sintilimab plus a bevacizumab biosimilar combined with transarterial chemoembolization for advanced hepatocellular carcinoma — Europe PMC PMID:41431101

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41431101
DOI
10.1097/md.0000000000046799
License (as archived)
solo-consultazione
Archived
2026-11-08T03:19:33.673Z
SHA-256 of the archived text
34eac582db73c007fae320e57e7e5c0d0d11ec4d32e3671007f486da5c5a5082
Stable URL of this page
https://metraipolis.com/documento/dc_7f15fb8d7969

How to cite

Efficacy and safety of sintilimab plus a bevacizumab biosimilar combined with transarterial chemoembolization for advanced hepatocellular carcinoma — Europe PMC PMID:41431101 — Europe PMC (en), https://europepmc.org/article/MED/41431101 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_7f15fb8d7969 (Metraipolis archive dc_7f15fb8d7969, sha256 34eac582db73c007fae320e57e7e5c0d0d11ec4d32e3671007f486da5c5a5082)
BibTeX
@misc{dc7f15fb8d7969,
  title = {Efficacy and safety of sintilimab plus a bevacizumab biosimilar combined with transarterial chemoembolization for advanced hepatocellular carcinoma — Europe PMC PMID:41431101},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41431101},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_7f15fb8d7969; sha256 34eac582db73c007fae320e57e7e5c0d0d11ec4d32e3671007f486da5c5a5082},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41431101. Agents can read the archived copy with the MCP tool read_document.